A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours-Reference-Cited by-同舟云学术

A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours

Published:2004-10-26 Issue:5 Volume:55 Page:453-460
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Sastre Javier,Paz-Ares Luis,Carcas Antonio,Alfonso Rosario,Gr�valos Cristina,Fr�as Jesus,Guerra Pedro,Pronk Linda,Cort�s-Funes Hern�n,D�az-Rubio Eduardo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-004-0915-x.pdf

Reference37 articles.

1. Conti JA, Kemeny NE, Saltz LB, et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709?715

2. Pitot HC, Wender DB, O?Connell MJ, et al (1997) Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910?2919

3. Rougier P, Bugat R, Douillard JY, et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251?260

4. Fukuoka M, Niitani H, Suzuki A, et al (1992) A phase II study of irinotecan, a new derivate of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16?20

5. Masuda N, Fukuoka M, Kusunoki Y, et al (1992) Irinotecan: a new derivate of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225?1229

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients;Medicine;2023-03-03

2. The Importance of Release of Proinflammatory Cytokines, ROS, and NO in Different Stages of Colon Carcinoma Growth and Metastasis After Treatment With Cytotoxic Drugs;Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics;2009-09-01

3. Clinical and pharmacogenetic factors associated with irinotecan toxicity;Cancer Treatment Reviews;2008-11

4. Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients;Current Clinical Pharmacology;2006-09-01